ý
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Delaware
|
|
20-4839882
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
Title of each class
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
The NASDAQ Global Market
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
|
|
|
|
|||
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
|
|
|
|
|
PART I
|
|
|
||
|
|
|
||
Item 1.
|
|
|
||
|
|
|
||
Item 1A.
|
|
|
||
|
|
|
||
Item 1B.
|
|
|
||
|
|
|
||
Item 2.
|
|
|
||
|
|
|
||
Item 3.
|
|
|
||
|
|
|
||
Item 4.
|
|
|
||
|
|
|||
PART II
|
|
|
||
|
|
|
||
Item 5.
|
|
|
||
|
|
|
||
Item 6.
|
|
|
||
|
|
|
||
Item 7.
|
|
|
||
|
|
|
||
Item 7A.
|
|
|
||
|
|
|
||
Item 8.
|
|
|
||
|
|
|
||
Item 9.
|
|
|
||
|
|
|
||
Item 9A.
|
|
|
||
|
|
|
||
Item 9B.
|
|
|
||
|
|
|||
PART III
|
|
|
||
|
|
|
||
Item 10.
|
|
|
||
|
|
|
||
Item 11.
|
|
|
||
|
|
|
||
Item 12.
|
|
|
||
|
|
|
||
Item 13.
|
|
|
||
|
|
|
||
Item 14.
|
|
|
||
|
|
|||
PART IV
|
|
|
||
|
|
|
||
Item 15.
|
|
|
||
|
|
|||
|
||||
|
|
|||
|
Item 1.
|
Business
|
•
|
using deuterium technology to develop deuterated product candidates with substantially improved safety, tolerability or efficacy profiles to compete directly with the non-deuterated compound in its approved indication and develop deuterated product candidates that are based on approved drugs but for new indications that we believe are promising in view of the known biology of the approved drug;
|
•
|
developing our deuterated product candidates quickly through proof-of-concept clinical trials, which could be as early as Phase 1, and then determining whether to advance it independently or with a partner; and
|
•
|
commercializing product candidates on our own, or with a strategic partner.
|
•
|
Improved metabolic profile.
An improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions or increase efficacy. Metabolic profile refers to the relative amounts and exposure profile of the parent drug and its metabolites in the body.
|
•
|
Increased half-life.
A longer half-life may decrease the number of doses that a patient is required to take per day or provide more consistent exposure of the compound in comparison to the corresponding non-deuterated compound, potentially improving the drug’s therapeutic profile. Half-life is usually defined as the time it takes for the body to clear half of a given concentration of the drug from the plasma.
|
•
|
Avoidance of undesirable metabolism:
By avoiding first pass metabolism, we may be able to improve oral bioavailability, which could potentially lead to better efficacy at a lower dose of drug. First pass metabolism is metabolism that occurs before the drug reaches the circulatory system.
|
•
|
our methods of evaluating candidate compounds for deuteration;
|
•
|
our bioanalytical methods for identifying and measuring metabolites formed by the
in vitro
and
in vivo
metabolism of deuterated compounds;
|
•
|
our analytical methods for evaluating how selective deuterium substitution affects different pharmacokinetic and metabolic parameters
in vitro
and
in vivo
systems; and
|
•
|
our methods to determine the degree of deuterium substitution in compounds we manufacture.
|
•
|
completion of nonclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice, or GLP, regulations;
|
•
|
production of well-characterized drug substance and drug product, and potentially matching placebos;
|
•
|
submission to the FDA of an investigational new drug application, or IND application, which allows human clinical trials to begin unless the FDA otherwise informs the drug’s sponsor within 30 days;
|
•
|
agreement by clinical investigators and their clinical trial sites, followed by approval by an independent institutional review board, or IRB, representing each clinical site, before the clinical trial may be initiated at that site;
|
•
|
performance of adequate and well-controlled human clinical trials in accordance with the FDA’s current Good Clinical Practices, or GCPs, to establish the safety and efficacy of the proposed drug product for each indication;
|
•
|
preparation and submission to the FDA of a New Drug Application, or NDA;
|
•
|
review of the NDA by an FDA advisory committee, where appropriate or if applicable;
|
•
|
satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or active ingredients thereof, are produced to assess compliance with current good manufacturing practices and to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity;
|
•
|
payment of user fees and securing FDA approval of the NDA; and
|
•
|
compliance with any post-approval requirements, including REMS and post-approval studies required by the FDA.
|
|
|
Phase 1:
|
The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.
|
|
|
Phase 2:
|
The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and dosage for Phase 3 studies.
|
|
|
Phase 3:
|
The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.
|
•
|
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
|
•
|
fines, warning letters or holds on post-approval clinical trials;
|
•
|
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;
|
•
|
product seizure or detention, or refusal to permit the import or export of products; or
|
•
|
injunctions or the imposition of civil or criminal penalties.
|
•
|
the required patent information has not been filed;
|
•
|
the listed patent has expired;
|
•
|
the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or
|
•
|
the listed patent is invalid, unenforceable or will not be infringed by the new product.
|
•
|
the federal healthcare Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
|
•
|
the federal civil and criminal false claims laws, including the False Claims Act, which imposes civil monetary penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
|
•
|
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes federal criminal and civil liability for, among other things, knowingly and willingly executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
|
•
|
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
|
•
|
the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;
|
•
|
the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests; and
|
•
|
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers.
|
Item 1A.
|
Risk Factors.
|
•
|
continue to develop and conduct nonclinical studies and clinical trials with respect to our product candidates;
|
•
|
seek to identify additional product candidates;
|
•
|
in-license or acquire additional product candidates;
|
•
|
seek marketing approvals for our product candidates that successfully complete clinical trials;
|
•
|
establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain marketing approval;
|
•
|
require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
|
•
|
maintain, expand and protect our intellectual property portfolio;
|
•
|
hire additional personnel;
|
•
|
add equipment and physical infrastructure to support our research and development; and
|
•
|
continue to implement the infrastructure necessary to support our product development and help us comply with our obligations as a public company.
|
•
|
the successful closing of our asset sale with Vertex;
|
•
|
the progress, timing, costs and results of clinical trials of, and research and nonclinical development efforts for, our product candidates and potential product candidates, including current and future clinical trials;
|
•
|
our current collaboration agreements and achievement of milestones under these agreements;
|
•
|
our ability to enter into and the terms and timing of any additional collaborations, licensing, product acquisition or other arrangements that we may establish;
|
•
|
the number of product candidates that we pursue and their development requirements;
|
•
|
the outcome, timing and costs of seeking regulatory approvals;
|
•
|
our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
|
•
|
the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and
|
•
|
the costs of operating as a public company.
|
•
|
requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes;
|
•
|
increasing our vulnerability to adverse changes in general economic, industry and market conditions;
|
•
|
subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;
|
•
|
limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and
|
•
|
placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.
|
•
|
in the case of CTP-656, our ability to enroll sufficient numbers of patients and in a timely manner to conduct our clinical trials;
|
•
|
in the case of CTP-656, if we need to develop it in combination with other agents to maximize its therapeutic and sales potential, our ability to license such combinations and our, or any collaborator's, ability to develop such combinations;
|
•
|
in the case of CTP-656, the ability of our current Phase 2 trial, or any Phase 2 trial that we can practicably conduct, to support progression to Phase 3 clinical trials;
|
•
|
in the case of CTP-656, our ability to agree with regulatory agencies on a Phase 3 trial design that we can practicably conduct;
|
•
|
in the case of CTP-543, our ability to safely and effectively treat moderate-to-severe alopecia areata;
|
•
|
successful completion of clinical trials;
|
•
|
receipt of marketing approvals from applicable regulatory authorities;
|
•
|
the performance of our future collaborators, if any, for our programs;
|
•
|
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
|
•
|
establishment of supply arrangements with third party raw materials suppliers and manufacturers;
|
•
|
our ability to manufacture or arrange for the manufacture of our active pharmaceutical ingredients and drug products
|
•
|
with sufficient quality, quantity, and reproducibility to support clinical trials and potential future commercialization;
|
•
|
establishment of arrangements with third party manufacturers to obtain finished drug products that are appropriately packaged for sale;
|
•
|
obtaining and maintaining patent, trade secret protection, regulatory exclusivity, and freedom to operate, both in the United States and internationally;
|
•
|
amount of commercial sales, if and when approved;
|
•
|
a continued acceptable safety profile of our programs following any marketing approval; and
|
•
|
agreement by third party payors to reimburse patients for the costs of treatment with our products, and the terms of such reimbursement.
|
•
|
be delayed in obtaining marketing approval for our product candidates;
|
•
|
not obtain marketing approval at all;
|
•
|
obtain approval for indications or patient populations that are not as broad as intended or desired;
|
•
|
obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;
|
•
|
be subject to additional post-marketing testing or other requirements; or
|
•
|
be required to remove the product from the market after obtaining marketing approval.
|
•
|
toxicity or serious adverse effects may be observed in our nonclinical studies causing us to delay or abandon clinical trials;
|
•
|
clinical trials of our product candidates may produce unfavorable or inconclusive results;
|
•
|
we, or our collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon product development programs;
|
•
|
the number of patients required for clinical trials of our product candidates may be larger than we, or our collaborators, anticipate, patient enrollment in these clinical trials may be slower than we, or our collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we, or our collaborators, anticipate;
|
•
|
our third party contractors or those of our collaborators, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of our collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or our collaborators in a timely manner or at all;
|
•
|
regulators or institutional review boards may not authorize us, our collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
|
•
|
we, or our collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
|
•
|
patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients or the sites from the clinical trial, increase the needed enrollment size for the clinical trial, extend the clinical trial’s duration or cause spurious results;
|
•
|
investigators may provide inaccurate or false data, resulting in spurious clinical results, an inadequate data set or regulators’ unwillingness to approve a product;
|
•
|
regulators or institutional review boards may require that we, or our collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate;
|
•
|
the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators’ clinical trial design or our or their interpretation of data from nonclinical studies and clinical trials;
|
•
|
the FDA or comparable foreign regulatory authorities may change their requirements for approvability for a given product or for an indication after we have initiated work based on their previous guidance;
|
•
|
the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
|
•
|
we, or our manufacturing vendors, may not produce, or may not consistently produce material that meets necessary specifications for commercialization;
|
•
|
the FDA or comparable foreign regulatory authorities may determine that our, or our manufacturing vendors, manufacturing or quality control processes fail to meet their specifications or guidelines; and
|
•
|
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.
|
•
|
the size and nature of the patient population;
|
•
|
the severity of the disease under investigation;
|
•
|
the proximity of patients to clinical sites;
|
•
|
the eligibility criteria for the trial;
|
•
|
the design of the clinical trial, including any requirement to halt current treatment in connection with the trial;
|
•
|
access to relevant clinical trial sites;
|
•
|
efforts to facilitate timely enrollment;
|
•
|
competing clinical trials;
|
•
|
support by relevant industry or patient organizations with influence over clinical trial sites; and
|
•
|
clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.
|
•
|
the efficacy and safety of the product;
|
•
|
the potential advantages of the product compared to alternative treatments;
|
•
|
the prevalence and severity of any side effects;
|
•
|
the clinical indications for which the product is approved;
|
•
|
whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;
|
•
|
limitations or warnings, including distribution or use restrictions or burdensome prescription requirements contained in the product’s approved labeling;
|
•
|
our ability, or the ability of our collaborators, to offer the product for sale at commercially acceptable prices;
|
•
|
the product’s convenience and ease of administration compared to alternative treatments;
|
•
|
the willingness of the target patient population to try, and of physicians to prescribe, the product;
|
•
|
the strength of sales, marketing and distribution support;
|
•
|
the approval of other new products for the same indications;
|
•
|
the extent and success of counter-detailing efforts by our competitors;
|
•
|
changes in the standard of care for the targeted indications for the product;
|
•
|
the timing of market introduction of our approved products as well as competitive products; and
|
•
|
availability and amount of reimbursement from government payors, managed care plans and other third party payors.
|
•
|
regulatory authorities may withdraw their approval of the drug and/or seize the drug;
|
•
|
we, or our collaborators, may be required to recall the drug or change the way the drug is administered;
|
•
|
additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug, including the addition of labeling statements, such as a “black box” warning or a contraindication;
|
•
|
we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
|
•
|
we, or our collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;
|
•
|
we, or our collaborators, could be sued and held liable for harm caused to patients; and
|
•
|
the drug may become less competitive.
|
•
|
deuterated analogs of existing non-deuterated compounds or newly designed deuterated compounds may not demonstrate satisfactory efficacy or other benefits, such as convenience of dosing, increased tolerability, enhanced formation of desirable active metabolites or reduced formation of toxic metabolites;
|
•
|
potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance; and
|
•
|
pharmaceutical and biotechnology companies have begun to claim deuterated analogs of their compounds in patent filings, resulting in otherwise promising deuterated product candidates already being covered by patents or patent applications.
|
•
|
decreased demand for our product candidates or products that we may develop;
|
•
|
injury to our reputation and significant negative media attention;
|
•
|
withdrawal of clinical trial participants;
|
•
|
significant costs to defend litigation;
|
•
|
distraction to our management diverting focus from business operations and strategy;
|
•
|
initiation of investigations by regulators;
|
•
|
product recalls, withdrawals or labeling, marketing or promotional restrictions;
|
•
|
substantial monetary awards to trial participants or patients;
|
•
|
loss of revenue; and
|
•
|
the inability to commercialize any products that we may develop.
|
•
|
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
|
•
|
collaborators may not perform their obligations as expected;
|
•
|
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators’ strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;
|
•
|
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
|
•
|
product candidates developed in collaboration with us, including in particular product candidates based on deuteration of a collaborator’s marketed drugs or advanced clinical candidates, may be viewed by our collaborators as competitive with
|
•
|
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;
|
•
|
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
|
•
|
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
|
•
|
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
|
•
|
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.
|
•
|
manufacturing delays if our third party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
|
•
|
the possible termination or nonrenewal of agreements by our third party contractors at a time that is costly or inconvenient for us;
|
•
|
potentially limited numbers of available contractors due to the need for uncommon equipment or expertise, or pre-existing conflicts of interest;
|
•
|
the possible breach by the third party contractors of our agreements with them;
|
•
|
possible theft of intellectual property or trade secrets;
|
•
|
possible theft of our materials, including starting materials, intermediates, active pharmaceutical ingredients, or drug products;
|
•
|
the failure of third party contractors to comply with applicable regulatory requirements;
|
•
|
the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;
|
•
|
possible contamination of our product during or after its manufacture;
|
•
|
possible interruptions in our contractors’ operations, including departure of key personnel, disruption due to merger and acquisitions activities or supply chain disruptions;
|
•
|
the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and
|
•
|
the possible misappropriation of our proprietary information, including our trade secrets and know-how.
|
•
|
restrictions on such products, manufacturers or manufacturing processes;
|
•
|
restrictions on the indication, patient population, or other parameters for which the drug is approved;
|
•
|
restrictions on the labeling or marketing of a product;
|
•
|
restrictions on product distribution or use;
|
•
|
requirements to conduct post-marketing studies or clinical trials;
|
•
|
warning letters or untitled letters;
|
•
|
withdrawal of the products from the market;
|
•
|
refusal to approve pending applications or supplements to approved applications that we submit;
|
•
|
recall of products;
|
•
|
fines, restitution or disgorgement of profits or revenues;
|
•
|
suspension or withdrawal of marketing approvals;
|
•
|
refusal to permit the import or export of products;
|
•
|
product seizure; or
|
•
|
injunctions or the imposition of civil or criminal penalties.
|
•
|
an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;
|
•
|
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
|
•
|
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;
|
•
|
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;
|
•
|
extension of manufacturers’ Medicaid rebate liability;
|
•
|
expansion of eligibility criteria for Medicaid programs;
|
•
|
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial arrangements with physicians and teaching hospitals;
|
•
|
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and
|
•
|
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
|
•
|
Anti-Kickback Statute
. The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;
|
•
|
False Claims Act
. The federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or
qui tam
actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $5,500 to $11,000 per false claim;
|
•
|
HIPAA
. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;
|
•
|
Transparency Requirements
. Federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members;
|
•
|
Controlled Substances Act
. The CSA regulates the handling of controlled substances such as JZP-386; and
|
•
|
Analogous State and Foreign Laws
. Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws can apply to sales or marketing arrangements and claims involving healthcare items or services. In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
|
•
|
the success or failure to close our asset sale with Vertex;
|
•
|
the success or failure of existing or new competitive products or technologies;
|
•
|
the timing, advancement of and results of nonclinical studies and clinical trials of any of our product candidates;
|
•
|
commencement or termination of collaborations for our development programs;
|
•
|
failure, delays, changes to or discontinuation of any of our development programs;
|
•
|
regulatory or legal developments in the United States and other countries;
|
•
|
regulatory actions relating to our product candidates;
|
•
|
developments or disputes concerning patent applications, issued patents or other proprietary rights;
|
•
|
the recruitment or departure of key personnel;
|
•
|
disclosures by our collaborators relating to our product candidates or competitive programs;
|
•
|
merger or acquisition activity of our collaborators;
|
•
|
the level of expenses related to any of our product candidates or clinical development programs;
|
•
|
the results of our efforts to develop additional product candidates or products;
|
•
|
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
|
•
|
announcement or expectation of additional financing efforts;
|
•
|
receipt or expectation of receipt of revenues such as milestones, royalties, grants and license fees;
|
•
|
sales of our common stock by us, our insiders or other stockholders;
|
•
|
programmed trading based on technical stock chart or other inputs;
|
•
|
portfolio restructuring by large shareholders;
|
•
|
addition or removal of our stock from stock indices;
|
•
|
variations in our financial results or those of companies that are perceived to be similar to us;
|
•
|
changes in estimates or recommendations by securities analysts that cover our stock;
|
•
|
actions by short-sellers or supporters of our stock, including social media postings or reports;
|
•
|
changes in the structure of healthcare payment systems;
|
•
|
market conditions in the pharmaceutical and biotechnology sectors;
|
•
|
legalization or the anticipation of possible legalization of drug reimportation from other countries;
|
•
|
actual or anticipated changes in FDA practices;
|
•
|
general economic, industry and market conditions; and
|
•
|
the other factors described in this “Risk Factors” section.
|
•
|
delay, defer or prevent a change in control;
|
•
|
entrench our management or the board of directors; or
|
•
|
impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.
|
•
|
establish a classified board of directors such that all members of the board are not elected at one time;
|
•
|
allow the authorized number of our directors to be changed only by resolution of our board of directors;
|
•
|
limit the manner in which stockholders can remove directors from the board;
|
•
|
establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;
|
•
|
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
|
•
|
limit who may call a special meeting of stockholders;
|
•
|
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
|
•
|
require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.
|
ITEM 5.
|
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities
|
|
|
High
|
|
Low
|
||||
Year Ended December 31, 2016
|
|
|
|
|
||||
First Quarter
|
|
$
|
19.69
|
|
|
$
|
12.16
|
|
Second Quarter
|
|
15.53
|
|
|
9.80
|
|
||
Third Quarter
|
|
12.28
|
|
|
9.47
|
|
||
Fourth Quarter
|
|
10.53
|
|
|
7.11
|
|
||
Year Ended December 31, 2015
|
|
|
|
|
||||
First Quarter
|
|
$
|
18.29
|
|
|
$
|
11.85
|
|
Second Quarter
|
|
17.84
|
|
|
13.11
|
|
||
Third Quarter
|
|
22.80
|
|
|
14.01
|
|
||
Fourth Quarter
|
|
25.04
|
|
|
18.47
|
|
ITEM 6.
|
Selected Financial Data
|
|
|
Years ended December 31,
|
||||||||||||||||||
(in thousands, except per share data)
|
|
2016
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
||||||||||
Results of Operations
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total revenue
|
|
$
|
174
|
|
|
$
|
66,729
|
|
|
$
|
8,576
|
|
|
$
|
25,408
|
|
|
$
|
12,849
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Research and development
|
|
$
|
36,983
|
|
|
$
|
28,885
|
|
|
$
|
27,474
|
|
|
$
|
21,790
|
|
|
$
|
24,193
|
|
General and administrative
|
|
14,358
|
|
|
13,056
|
|
|
11,700
|
|
|
8,028
|
|
|
7,266
|
|
|||||
Total operating expenses
|
|
51,341
|
|
|
41,941
|
|
|
39,174
|
|
|
29,818
|
|
|
31,459
|
|
|||||
(Loss) Income from operations
|
|
(51,167
|
)
|
|
24,788
|
|
|
(30,598
|
)
|
|
(4,410
|
)
|
|
(18,610
|
)
|
|||||
Interest and other income (expense), net
|
|
447
|
|
|
(185
|
)
|
|
(1,101
|
)
|
|
(1,646
|
)
|
|
(1,834
|
)
|
|||||
Provision for income taxes
|
|
—
|
|
|
429
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Net (loss) income
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,699
|
)
|
|
$
|
(6,056
|
)
|
|
$
|
(20,444
|
)
|
Accretion on redeemable convertible preferred stock
|
|
—
|
|
|
—
|
|
|
(55
|
)
|
|
(396
|
)
|
|
(388
|
)
|
|||||
Net (loss) income applicable to common stockholders - basic and diluted
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,754
|
)
|
|
$
|
(6,452
|
)
|
|
$
|
(20,832
|
)
|
Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net (loss) income per share applicable to common stockholders - basic
|
|
$
|
(2.28
|
)
|
|
$
|
1.14
|
|
|
$
|
(2.00
|
)
|
|
$
|
(4.99
|
)
|
|
$
|
(16.15
|
)
|
Net (loss) income per share applicable to common stockholders - diluted
|
|
$
|
(2.28
|
)
|
|
$
|
1.09
|
|
|
$
|
(2.00
|
)
|
|
$
|
(4.99
|
)
|
|
$
|
(16.15
|
)
|
Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders - basic
|
|
22,233
|
|
|
21,152
|
|
|
15,842
|
|
|
1,292
|
|
|
1,290
|
|
|||||
Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders - diluted
|
|
22,233
|
|
|
22,267
|
|
|
15,842
|
|
|
1,292
|
|
|
1,290
|
|
|||||
Financial Condition
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
|
$
|
40,555
|
|
|
$
|
92,510
|
|
|
$
|
13,396
|
|
|
$
|
9,638
|
|
|
$
|
7,490
|
|
Investments, available for sale
|
|
55,630
|
|
|
49,680
|
|
|
65,836
|
|
|
23,039
|
|
|
20,067
|
|
|||||
Working capital
|
|
92,159
|
|
|
137,481
|
|
|
63,102
|
|
|
18,128
|
|
|
20,940
|
|
|||||
Total assets
|
|
100,395
|
|
|
146,932
|
|
|
84,454
|
|
|
39,773
|
|
|
33,129
|
|
|||||
Deferred revenue
|
|
10,050
|
|
|
10,170
|
|
|
15,821
|
|
|
19,631
|
|
|
2,750
|
|
|||||
Loan payable, net of discount
|
|
—
|
|
|
—
|
|
|
7,101
|
|
|
14,919
|
|
|
19,731
|
|
|||||
Redeemable convertible preferred stock
|
|
—
|
|
|
—
|
|
|
—
|
|
|
112,244
|
|
|
111,848
|
|
|||||
Total stockholders’ equity (deficit)
|
|
85,594
|
|
|
130,635
|
|
|
54,825
|
|
|
(112,104
|
)
|
|
(106,687
|
)
|
ITEM 7.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
•
|
employee-related expenses, including salary, benefits, travel and stock-based compensation expense;
|
•
|
expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;
|
•
|
the cost of acquiring, developing and manufacturing clinical trial materials;
|
•
|
facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies;
|
•
|
platform-related lab expenses, which includes costs related to synthesis, analysis and
in vitro
and
in vivo
characterization of deuterated compounds to support the selection and progression of potential product candidates;
|
•
|
expenses related to consultants and advisors; and
|
•
|
costs associated with nonclinical activities and regulatory operations.
|
•
|
the scope and rate of progress of our ongoing as well as any additional clinical trials and other research and development activities;
|
•
|
conduct of and results from ongoing as well as any additional clinical trials and research and development activities;
|
•
|
significant and changing government regulation;
|
•
|
the terms and timing and receipt of any regulatory approvals;
|
•
|
the performance of our collaborators;
|
•
|
our ability to manufacture any of our product candidates that we are developing or may develop in the future; and
|
•
|
the expense and success of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, including potential claims that we infringe other parties' intellectual property.
|
•
|
revenue recognition;
|
•
|
accrued research and development expense; and
|
•
|
stock-based compensation.
|
•
|
Option Arrangements
. An option to obtain an exclusive license is considered substantive if, at the inception of the arrangement, we are at risk as to whether the collaboration partner will choose to exercise the option. Factors that we consider in evaluating whether an option is substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the arrangement without exercising the option, the cost to exercise the option and the
|
•
|
Exclusive Licenses
. We recognize arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria included in ASC Topic 605
Revenue Recognition
are satisfied for that particular unit of accounting. We will recognize as revenue arrangement consideration attributed to exclusive licenses that have standalone value from the other deliverables to be provided in an arrangement upon delivery. We will recognize as revenue arrangement consideration attributed to exclusive licenses that do not have standalone value from the other deliverables to be provided in an arrangement over our estimated performance period as the arrangement would be accounted for as a single, combined unit of accounting.
|
•
|
Research and Development Services
. We recognize revenue associated with research and development services over the associated period of performance. If there is no discernible pattern of performance and/or objectively measurable performance measures do not exist, then we recognize revenue on a straight-line basis over the period we are expected to complete our performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then we recognize revenue under the arrangement using the proportional performance method, which requires us to make certain estimates when determining the proportion of services rendered in relation to the total services expected to be rendered.
|
•
|
the consideration is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone;
|
•
|
the consideration relates solely to past performance; and
|
•
|
the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
|
•
|
contract research organizations in connection with clinical trials;
|
•
|
investigative sites in connection with clinical trials;
|
•
|
vendors in connection with nonclinical development activities; and
|
•
|
vendors related to product manufacturing, development and distribution of clinical supplies.
|
|
|
Year ended December 31,
|
|||||||
|
|
2016
|
|
2015
|
|
2014
|
|||
Expected volatility
|
|
78.29
|
%
|
|
73.38
|
%
|
|
80.94
|
%
|
Expected term
|
|
6.0 years
|
|
|
6.0 years
|
|
|
6.0 years
|
|
Risk-free interest rate
|
|
1.36
|
%
|
|
1.69
|
%
|
|
1.90
|
%
|
Expected dividend yield
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
|
Year ended December 31,
|
|
|
||||||||
(in thousands)
|
|
2016
|
|
2015
|
|
Change
|
||||||
Revenue:
|
|
|
|
|
|
|
||||||
License and research and development revenue
|
|
$
|
174
|
|
|
$
|
6,574
|
|
|
$
|
(6,400
|
)
|
Other revenue
|
|
—
|
|
|
50,155
|
|
|
(50,155
|
)
|
|||
Milestone revenue
|
|
—
|
|
|
10,000
|
|
|
(10,000
|
)
|
|||
Total revenue
|
|
174
|
|
|
66,729
|
|
|
(66,555
|
)
|
|||
Operating expenses:
|
|
|
|
|
|
|
||||||
Research and development
|
|
36,983
|
|
|
28,885
|
|
|
8,098
|
|
|||
General and administrative
|
|
14,358
|
|
|
13,056
|
|
|
1,302
|
|
|||
Total operating expenses
|
|
51,341
|
|
|
41,941
|
|
|
9,400
|
|
|||
(Loss) Income from operations
|
|
(51,167
|
)
|
|
24,788
|
|
|
(75,955
|
)
|
|||
Investment income
|
|
447
|
|
|
124
|
|
|
323
|
|
|||
Interest and other expense
|
|
—
|
|
|
(309
|
)
|
|
309
|
|
|||
(Loss) Income before income taxes
|
|
(50,720
|
)
|
|
24,603
|
|
|
(75,323
|
)
|
|||
Provision for income taxes
|
|
—
|
|
|
429
|
|
|
(429
|
)
|
|||
Net (loss) income
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(74,894
|
)
|
•
|
$7.2 million related to our collaboration with Celgene, $1.1 million of which is attributable to the CTP-730 program and is currently expected to be recognized as revenue in the next twelve months as we satisfy our remaining research
|
•
|
$0.1 million related to our collaboration with Jazz Pharmaceuticals and associated with research and development services to be performed and recognized as revenue over the estimated remaining performance period of 24 months; and
|
•
|
$2.8 million related to a payment received from GSK that we will not recognize as revenue until all repayment obligations lapse in 2018.
|
|
|
Year ended December 31,
|
||||||
(in thousands)
|
|
2016
|
|
2015
|
||||
|
|
|
|
|
||||
CTP-656 external costs
|
|
9,592
|
|
|
3,759
|
|
||
CTP-543 external costs
|
|
7,603
|
|
|
2,064
|
|
||
CTP-730 external costs
|
|
31
|
|
|
2,711
|
|
||
JZP-386 external costs
|
|
19
|
|
|
1,084
|
|
||
External costs for other programs
|
|
1,732
|
|
|
2,622
|
|
||
Employee and contractor-related expenses
|
|
14,523
|
|
|
13,507
|
|
||
Facility and other expenses
|
|
3,483
|
|
|
3,138
|
|
||
Total research and development expenses
|
|
$
|
36,983
|
|
|
$
|
28,885
|
|
|
|
Year ended December 31,
|
|
|
||||||||
(in thousands)
|
|
2015
|
|
2014
|
|
Change
|
||||||
Revenue:
|
|
|
|
|
|
|
||||||
License and research and development revenue
|
|
$
|
6,574
|
|
|
$
|
6,576
|
|
|
$
|
(2
|
)
|
Other revenue
|
|
50,155
|
|
|
—
|
|
|
50,155
|
|
|||
Milestone revenue
|
|
10,000
|
|
|
2,000
|
|
|
8,000
|
|
|||
Total revenue
|
|
66,729
|
|
|
8,576
|
|
|
58,153
|
|
|||
Operating expenses:
|
|
|
|
|
|
|
||||||
Research and development
|
|
28,885
|
|
|
27,474
|
|
|
1,411
|
|
|||
General and administrative
|
|
13,056
|
|
|
11,700
|
|
|
1,356
|
|
|||
Total operating expenses
|
|
41,941
|
|
|
39,174
|
|
|
2,767
|
|
|||
Income (Loss) from operations
|
|
24,788
|
|
|
(30,598
|
)
|
|
55,386
|
|
|||
Investment income
|
|
124
|
|
|
49
|
|
|
75
|
|
|||
Interest and other expense
|
|
(309
|
)
|
|
(1,150
|
)
|
|
841
|
|
|||
Income (Loss) before income taxes
|
|
24,603
|
|
|
(31,699
|
)
|
|
56,302
|
|
|||
Provision for income taxes
|
|
429
|
|
|
—
|
|
|
429
|
|
|||
Net income (loss)
|
|
$
|
24,174
|
|
|
$
|
(31,699
|
)
|
|
$
|
55,873
|
|
|
|
Year ended December 31,
|
||||||
(in thousands)
|
|
2015
|
|
2014
|
||||
|
|
|
|
|
||||
CTP-656 external costs
|
|
3,759
|
|
|
1,063
|
|
||
CTP-543 external costs
|
|
2,064
|
|
|
73
|
|
||
CTP-730 external costs
|
|
2,711
|
|
|
1,904
|
|
||
JZP-386 external costs
|
|
1,084
|
|
|
2,207
|
|
||
External costs for other programs
|
|
2,622
|
|
|
8,621
|
|
||
Employee and contractor-related expenses
|
|
13,507
|
|
|
10,523
|
|
||
Facility and other expenses
|
|
3,138
|
|
|
3,083
|
|
||
Total research and development expenses
|
|
$
|
28,885
|
|
|
$
|
27,474
|
|
|
|
Year ended December 31,
|
||||||||||
(in thousands)
|
|
2016
|
|
2015
|
|
2014
|
||||||
Net cash provided by (used in):
|
|
|
|
|
|
|
||||||
Operating activities
|
|
$
|
(45,343
|
)
|
|
$
|
23,061
|
|
|
$
|
(29,760
|
)
|
Investing activities
|
|
(7,213
|
)
|
|
14,569
|
|
|
(44,452
|
)
|
|||
Financing activities
|
|
601
|
|
|
41,484
|
|
|
77,970
|
|
|||
Net (decrease) increase in cash and cash equivalents
|
|
$
|
(51,955
|
)
|
|
$
|
79,114
|
|
|
$
|
3,758
|
|
(1)
|
Consists of future lease payments under the operating lease for our office and laboratory space at 99 Hayden Avenue, Lexington, Massachusetts. The operating lease expires on September 30, 2018.
|
ITEM 7A.
|
Quantitative and Qualitative Disclosures About Market Risk
|
ITEM 8.
|
Financial Statements and Supplementary Data
|
|
|
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
|
||||||||
|
|
December 31,
|
||||||
|
|
2016
|
|
2015
|
||||
|
|
(Amounts in thousands, except
share and per share data)
|
||||||
Assets
|
|
|
|
|
||||
Current assets:
|
|
|
|
|
||||
Cash and cash equivalents
|
|
$
|
40,555
|
|
|
$
|
92,510
|
|
Investments, available for sale
|
|
55,630
|
|
|
49,680
|
|
||
Interest receivable
|
|
164
|
|
|
181
|
|
||
Accounts receivable
|
|
27
|
|
|
70
|
|
||
Prepaid expenses and other current assets
|
|
1,353
|
|
|
1,667
|
|
||
Total current assets
|
|
97,729
|
|
|
144,108
|
|
||
Property and equipment, net
|
|
2,199
|
|
|
2,346
|
|
||
Restricted cash
|
|
400
|
|
|
400
|
|
||
Other assets
|
|
67
|
|
|
78
|
|
||
Total assets
|
|
$
|
100,395
|
|
|
$
|
146,932
|
|
Liabilities and stockholders’ equity
|
|
|
|
|
||||
Current liabilities:
|
|
|
|
|
||||
Accounts payable
|
|
$
|
545
|
|
|
$
|
501
|
|
Accrued expenses and other liabilities
|
|
3,853
|
|
|
4,772
|
|
||
Income taxes payable
|
|
—
|
|
|
75
|
|
||
Deferred revenue, current portion
|
|
1,172
|
|
|
1,279
|
|
||
Total current liabilities
|
|
5,570
|
|
|
6,627
|
|
||
Deferred revenue, net of current portion
|
|
8,878
|
|
|
8,891
|
|
||
Deferred lease incentive, net of current portion
|
|
249
|
|
|
573
|
|
||
Deferred rent, net of current portion
|
|
104
|
|
|
206
|
|
||
Total liabilities
|
|
14,801
|
|
|
16,297
|
|
||
Commitments (Note 12)
|
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
||||
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding in 2016 and 2015, respectively
|
|
—
|
|
|
—
|
|
||
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 22,319,516 and 22,166,803 shares issued and 22,316,982 and 22,165,166 outstanding in 2016 and 2015, respectively
|
|
22
|
|
|
22
|
|
||
Additional paid-in capital
|
|
257,461
|
|
|
251,793
|
|
||
Accumulated other comprehensive loss
|
|
(7
|
)
|
|
(18
|
)
|
||
Accumulated deficit
|
|
(171,882
|
)
|
|
(121,162
|
)
|
||
Total stockholders’ equity
|
|
85,594
|
|
|
130,635
|
|
||
Total liabilities and stockholders’ equity
|
|
$
|
100,395
|
|
|
$
|
146,932
|
|
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
|
||||||||||||
|
|
Year ended
December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
(Amounts in thousands, except per
share data)
|
||||||||||
Revenue:
|
|
|
|
|
|
|
||||||
License and research and development revenue
|
|
$
|
174
|
|
|
$
|
6,574
|
|
|
$
|
6,576
|
|
Other revenue (Note 14)
|
|
—
|
|
|
50,155
|
|
|
—
|
|
|||
Milestone revenue
|
|
—
|
|
|
10,000
|
|
|
2,000
|
|
|||
Total revenue
|
|
174
|
|
|
66,729
|
|
|
8,576
|
|
|||
Operating expenses:
|
|
|
|
|
|
|
||||||
Research and development
|
|
36,983
|
|
|
28,885
|
|
|
27,474
|
|
|||
General and administrative
|
|
14,358
|
|
|
13,056
|
|
|
11,700
|
|
|||
Total operating expenses
|
|
51,341
|
|
|
41,941
|
|
|
39,174
|
|
|||
(Loss) Income from operations
|
|
(51,167
|
)
|
|
24,788
|
|
|
(30,598
|
)
|
|||
Investment income
|
|
447
|
|
|
124
|
|
|
49
|
|
|||
Interest and other expense
|
|
—
|
|
|
(309
|
)
|
|
(1,150
|
)
|
|||
(Loss) Income before income taxes
|
|
(50,720
|
)
|
|
24,603
|
|
|
(31,699
|
)
|
|||
Provision for income taxes
|
|
—
|
|
|
429
|
|
|
—
|
|
|||
Net (loss) income
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,699
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
||||||
Unrealized income (loss) on investments
|
|
11
|
|
|
(4
|
)
|
|
(18
|
)
|
|||
Comprehensive (loss) income
|
|
$
|
(50,709
|
)
|
|
$
|
24,170
|
|
|
$
|
(31,717
|
)
|
Reconciliation of net (loss) income to net (loss) income applicable to common stockholders:
|
|
|
|
|
|
|
||||||
Net (loss) income
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,699
|
)
|
Accretion on redeemable convertible preferred stock
|
|
—
|
|
|
—
|
|
|
(55
|
)
|
|||
Net (loss) income applicable to common stockholders—basic and diluted
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,754
|
)
|
Net (loss) income per share applicable to common stockholders—basic
|
|
$
|
(2.28
|
)
|
|
$
|
1.14
|
|
|
$
|
(2.00
|
)
|
Net (loss) income per share applicable to common stockholders—diluted
|
|
$
|
(2.28
|
)
|
|
$
|
1.09
|
|
|
$
|
(2.00
|
)
|
Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders—basic
|
|
22,233
|
|
|
21,152
|
|
|
15,842
|
|
|||
Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders—diluted
|
|
22,233
|
|
|
22,267
|
|
|
15,842
|
|
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
|||||||||||||||||||||||||||||||||
|
|
Redeemable convertible preferred stock
|
|
Common Stock
|
|
Additional paid-in capital
|
|
Accumulated other comprehensive income
|
|
Accumulated deficit
|
|
Total stockholders’ equity (deficit)
|
|||||||||||||||||||||
|
|
Shares
|
|
Carrying
value
|
|
Issued
|
|
In Treasury
|
|
Amount
|
|
||||||||||||||||||||||
|
|
(in thousands)
|
|||||||||||||||||||||||||||||||
Balance at December 31, 2013
|
|
56,047
|
|
|
$
|
112,244
|
|
|
1,298
|
|
|
—
|
|
|
$
|
1
|
|
|
$
|
1,528
|
|
|
$
|
4
|
|
|
$
|
(113,637
|
)
|
|
$
|
(112,104
|
)
|
Accretion of redeemable convertible preferred stock to redemption value
|
|
—
|
|
|
55
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(55
|
)
|
|
—
|
|
|
—
|
|
|
(55
|
)
|
||||||
Proceeds from IPO, net of underwriting discounts and offering expenses
|
|
—
|
|
|
—
|
|
|
6,650
|
|
|
|
|
7
|
|
|
83,112
|
|
|
|
|
|
|
83,119
|
|
|||||||||
Conversion of preferred stock into common stock
|
|
(56,047
|
)
|
|
(112,299
|
)
|
|
9,920
|
|
|
|
|
10
|
|
|
112,289
|
|
|
|
|
|
|
112,299
|
|
|||||||||
Reclassification of warrant
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
581
|
|
|
|
|
|
|
581
|
|
|||||||||||
Exercise of stock options
|
|
—
|
|
|
—
|
|
|
366
|
|
|
—
|
|
|
—
|
|
|
1,009
|
|
|
—
|
|
|
—
|
|
|
1,009
|
|
||||||
Unrealized gain (loss) on short-term investments
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
(18
|
)
|
|
|
|
(18
|
)
|
|||||||||||
Stock-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,693
|
|
|
—
|
|
|
—
|
|
|
1,693
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(31,699
|
)
|
|
(31,699
|
)
|
||||||
Balance at December 31, 2014
|
|
—
|
|
|
$
|
—
|
|
|
18,234
|
|
|
—
|
|
|
$
|
18
|
|
|
$
|
200,157
|
|
|
$
|
(14
|
)
|
|
$
|
(145,336
|
)
|
|
$
|
54,825
|
|
Proceeds from public offering of common stock, net of underwriting discounts and offering expenses
|
|
—
|
|
|
—
|
|
|
3,300
|
|
|
—
|
|
|
3
|
|
|
46,682
|
|
|
—
|
|
|
—
|
|
|
46,685
|
|
||||||
Exercise of stock options
|
|
—
|
|
|
—
|
|
|
633
|
|
|
2
|
|
|
1
|
|
|
1,843
|
|
|
—
|
|
|
—
|
|
|
1,844
|
|
||||||
Unrealized gain (loss) on short-term investments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
—
|
|
|
(4
|
)
|
||||||
Stock-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,981
|
|
|
—
|
|
|
—
|
|
|
2,981
|
|
||||||
Income tax benefit from option exercises
|
|
|
|
|
|
|
|
|
|
|
|
130
|
|
|
|
|
|
|
130
|
|
|||||||||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
24,174
|
|
|
24,174
|
|
||||||
Balance at December 31, 2015
|
|
—
|
|
|
$
|
—
|
|
|
22,167
|
|
|
2
|
|
|
$
|
22
|
|
|
$
|
251,793
|
|
|
$
|
(18
|
)
|
|
$
|
(121,162
|
)
|
|
$
|
130,635
|
|
Exercise of stock options
|
|
—
|
|
|
—
|
|
|
153
|
|
|
1
|
|
|
—
|
|
|
601
|
|
|
—
|
|
|
—
|
|
|
601
|
|
||||||
Unrealized gain (loss) on short-term investments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11
|
|
|
—
|
|
|
11
|
|
||||||
Stock-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5,067
|
|
|
—
|
|
|
—
|
|
|
5,067
|
|
||||||
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(50,720
|
)
|
|
(50,720
|
)
|
||||||
Balance at December 31, 2016
|
|
—
|
|
|
$
|
—
|
|
|
22,320
|
|
|
3
|
|
|
$
|
22
|
|
|
$
|
257,461
|
|
|
$
|
(7
|
)
|
|
$
|
(171,882
|
)
|
|
$
|
85,594
|
|
CONCERT PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||||||
|
|
Year ended
December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
(in thousands)
|
||||||||||
Operating activities
|
|
|
|
|
|
|
||||||
Net (loss) income
|
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,699
|
)
|
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
|
|
|
|
|
|
|
||||||
Depreciation and amortization
|
|
893
|
|
|
785
|
|
|
1,052
|
|
|||
Stock-based compensation expense
|
|
5,067
|
|
|
2,981
|
|
|
1,693
|
|
|||
Accretion of premiums and discounts on investments
|
|
504
|
|
|
715
|
|
|
833
|
|
|||
Amortization of discount on loan payable
|
|
—
|
|
|
74
|
|
|
98
|
|
|||
Amortization of deferred financing costs
|
|
—
|
|
|
29
|
|
|
38
|
|
|||
Re-measurement of warrant to purchase redeemable securities
|
|
—
|
|
|
—
|
|
|
117
|
|
|||
Amortization of deferred lease incentive
|
|
(315
|
)
|
|
(308
|
)
|
|
(367
|
)
|
|||
Loss on disposal of asset
|
|
2
|
|
|
4
|
|
|
—
|
|
|||
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
||||||
Accounts receivable
|
|
43
|
|
|
951
|
|
|
(851
|
)
|
|||
Interest receivable
|
|
17
|
|
|
81
|
|
|
(170
|
)
|
|||
Prepaid expenses and other current assets
|
|
314
|
|
|
(491
|
)
|
|
(137
|
)
|
|||
Restricted cash
|
|
—
|
|
|
—
|
|
|
306
|
|
|||
Other assets
|
|
11
|
|
|
23
|
|
|
82
|
|
|||
Accounts payable
|
|
44
|
|
|
(90
|
)
|
|
(32
|
)
|
|||
Accrued expenses and other liabilities
|
|
(957
|
)
|
|
(223
|
)
|
|
2,863
|
|
|||
Landlord lease incentive
|
|
—
|
|
|
—
|
|
|
350
|
|
|||
Income taxes payable
|
|
(75
|
)
|
|
75
|
|
|
—
|
|
|||
Deferred rent
|
|
(51
|
)
|
|
(68
|
)
|
|
(126
|
)
|
|||
Deferred revenue
|
|
(120
|
)
|
|
(5,651
|
)
|
|
(3,810
|
)
|
|||
Net cash (used in) provided by operating activities
|
|
(45,343
|
)
|
|
23,061
|
|
|
(29,760
|
)
|
|||
Investing activities
|
|
|
|
|
|
|
||||||
Purchases of property and equipment
|
|
(770
|
)
|
|
(868
|
)
|
|
(804
|
)
|
|||
Purchases of investments
|
|
(132,344
|
)
|
|
(163,025
|
)
|
|
(89,188
|
)
|
|||
Maturities of investments
|
|
125,901
|
|
|
178,462
|
|
|
45,540
|
|
|||
Net cash (used in) provided by investing activities
|
|
(7,213
|
)
|
|
14,569
|
|
|
(44,452
|
)
|
|||
Financing activities
|
|
|
|
|
|
|
||||||
Principal payments on loan payable
|
|
—
|
|
|
(7,175
|
)
|
|
(7,916
|
)
|
|||
Repayment of leasehold improvement loan
|
|
—
|
|
|
—
|
|
|
(266
|
)
|
|||
Proceeds from public offering of common stock, net of underwriting discounts and commissions
|
|
—
|
|
|
46,995
|
|
|
86,579
|
|
|||
Proceeds from exercise of stock options
|
|
601
|
|
|
1,844
|
|
|
1,009
|
|
|||
Income tax benefit from exercise of stock options
|
|
—
|
|
|
130
|
|
|
—
|
|
|||
Payment of public offering costs
|
|
—
|
|
|
(310
|
)
|
|
(1,436
|
)
|
|||
Net cash provided by (used in) financing activities
|
|
601
|
|
|
41,484
|
|
|
77,970
|
|
|||
Net increase in cash and cash equivalents
|
|
(51,955
|
)
|
|
79,114
|
|
|
3,758
|
|
|||
Cash and cash equivalents at beginning of period
|
|
92,510
|
|
|
13,396
|
|
|
9,638
|
|
|||
Cash and cash equivalents at end of period
|
|
$
|
40,555
|
|
|
$
|
92,510
|
|
|
$
|
13,396
|
|
Supplemental cash flow information:
|
|
|
|
|
|
|
||||||
Cash paid for income taxes
|
|
$
|
85
|
|
|
$
|
225
|
|
|
$
|
—
|
|
Cash paid for interest
|
|
$
|
—
|
|
|
$
|
287
|
|
|
$
|
992
|
|
Purchases of property and equipment unpaid at period end
|
|
$
|
20
|
|
|
$
|
42
|
|
|
$
|
60
|
|
•
|
Level 1—quoted prices for identical instruments in active markets;
|
•
|
Level 2—quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
|
•
|
Level 3—valuations derived from valuation techniques in which one or more significant value drivers are unobservable.
|
•
|
Persuasive evidence of an arrangement exists;
|
•
|
Delivery has occurred or services have been rendered;
|
•
|
The seller’s price to the buyer is fixed or determinable; and
|
•
|
Collectability is reasonably assured.
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
December 31, 2016
|
|
|
|
|
|
|
|
|
||||||||
Cash equivalents:
|
|
|
|
|
|
|
|
|
||||||||
Money market funds
|
|
26,257
|
|
|
—
|
|
|
—
|
|
|
26,257
|
|
||||
U.S. Treasury obligations
|
|
—
|
|
|
1,001
|
|
|
—
|
|
|
1,001
|
|
||||
Investments, available for sale:
|
|
|
|
|
|
|
|
|
||||||||
U.S. Treasury obligations
|
|
10,034
|
|
|
5,503
|
|
|
—
|
|
|
15,537
|
|
||||
Government agency securities
|
|
24,545
|
|
|
15,548
|
|
|
—
|
|
|
40,093
|
|
||||
Total
|
|
$
|
60,836
|
|
|
$
|
22,052
|
|
|
$
|
—
|
|
|
$
|
82,888
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
December 31, 2015
|
|
|
|
|
|
|
|
|
||||||||
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|||||||
Money market funds
|
|
52,221
|
|
|
—
|
|
|
—
|
|
|
52,221
|
|
||||
U.S. Treasury obligations
|
|
5,001
|
|
|
—
|
|
|
—
|
|
|
5,001
|
|
||||
Government agency securities
|
|
—
|
|
|
34,390
|
|
|
—
|
|
|
34,390
|
|
||||
Investments, available for sale:
|
|
|
|
|
|
|
|
|
||||||||
U.S. Treasury obligations
|
|
9,781
|
|
|
—
|
|
|
—
|
|
|
9,781
|
|
||||
Government agency securities
|
|
19,578
|
|
|
20,321
|
|
|
—
|
|
|
39,899
|
|
||||
Total
|
|
$
|
86,581
|
|
|
$
|
54,711
|
|
|
$
|
—
|
|
|
$
|
141,292
|
|
|
|
Average
maturity
|
|
Amortized
cost
|
|
Unrealized
gains
|
|
Unrealized
losses
|
|
Fair
value
|
|||||||||
December 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Cash
|
|
|
|
$
|
13,297
|
|
—
|
|
—
|
|
|
—
|
|
|
$
|
13,297
|
|
||
Money market funds
|
|
|
|
26,257
|
|
—
|
|
—
|
|
|
—
|
|
|
26,257
|
|
||||
U.S. Treasury obligations
|
|
31 days
|
|
1,001
|
|
—
|
|
—
|
|
|
—
|
|
|
1,001
|
|
||||
Cash and cash equivalents
|
|
|
|
$
|
40,555
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
40,555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
U.S. Treasury obligations
|
|
125 days
|
|
$
|
15,534
|
|
|
4
|
|
|
(1
|
)
|
|
$
|
15,537
|
|
|||
Government agency securities
|
|
140 days
|
|
40,103
|
|
|
1
|
|
|
(11
|
)
|
|
40,093
|
|
|||||
Investments, available for sale
|
|
|
|
$
|
55,637
|
|
|
$
|
5
|
|
|
$
|
(12
|
)
|
|
$
|
55,630
|
|
|
|
Average
maturity
|
|
Amortized
cost
|
|
Unrealized
gains
|
|
Unrealized
losses
|
|
Fair
value
|
||||||||
December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
||||||||
Cash
|
|
|
|
$
|
898
|
|
|
—
|
|
|
—
|
|
|
$
|
898
|
|
||
Money market funds
|
|
|
|
52,221
|
|
|
—
|
|
|
—
|
|
|
52,221
|
|
||||
U.S. Treasury obligations
|
|
31 days
|
|
5,002
|
|
|
—
|
|
|
(1
|
)
|
|
5,001
|
|
||||
Government agency securities
|
|
41 days
|
|
34,389
|
|
|
1
|
|
|
—
|
|
|
34,390
|
|
||||
Cash and cash equivalents
|
|
|
|
$
|
92,510
|
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
|
$
|
92,510
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
U.S. Treasury obligations
|
|
42 days
|
|
$
|
9,785
|
|
|
—
|
|
|
(4
|
)
|
|
$
|
9,781
|
|
||
Government agency securities
|
|
104 days
|
|
39,913
|
|
|
1
|
|
|
(15
|
)
|
|
39,899
|
|
||||
Investments, available for sale
|
|
|
|
$
|
49,698
|
|
|
$
|
1
|
|
|
$
|
(19
|
)
|
|
$
|
49,680
|
|
|
|
Estimated useful life
(in years)
|
|
December 31,
2016
|
|
December 31,
2015 |
||||
Laboratory equipment
|
|
5
|
|
$
|
2,128
|
|
|
$
|
1,769
|
|
Computer, telephone and office equipment
|
|
3
|
|
207
|
|
|
211
|
|
||
Software
|
|
3
|
|
192
|
|
|
84
|
|
||
Leasehold improvements
|
|
Lesser of useful life or remaining lease term
|
|
6,548
|
|
|
6,496
|
|
||
|
|
|
|
9,075
|
|
|
8,560
|
|
||
Less accumulated depreciation and amortization
|
|
|
|
(6,876
|
)
|
|
(6,214
|
)
|
||
|
|
|
|
$
|
2,199
|
|
|
$
|
2,346
|
|
|
|
December 31,
2016
|
|
December 31,
2015 |
||||
Accrued professional fees and other
|
|
$
|
487
|
|
|
$
|
732
|
|
Employee compensation and benefits
|
|
2,010
|
|
|
2,503
|
|
||
Research and development expenses
|
|
930
|
|
|
1,171
|
|
||
Deferred lease incentive, current portion
|
|
324
|
|
|
315
|
|
||
Deferred rent, current portion
|
|
102
|
|
|
51
|
|
||
|
|
$
|
3,853
|
|
|
$
|
4,772
|
|
|
|
Year ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
|
|
(in thousands, except per share data)
|
||||||||||
Weighted average fair value of options granted, per option
|
|
$
|
10.42
|
|
|
$
|
10.27
|
|
|
$
|
6.69
|
|
Aggregate grant date fair value of options vested during the year
|
|
$
|
4,614
|
|
|
$
|
3,470
|
|
|
$
|
629
|
|
Total cash received from exercises of stock options
|
|
$
|
601
|
|
|
$
|
1,844
|
|
|
$
|
1,009
|
|
Total intrinsic value of stock options exercised
|
|
$
|
1,160
|
|
|
$
|
9,126
|
|
|
$
|
2,363
|
|
|
|
Year ended December 31,
|
|||||||
|
|
2016
|
|
2015
|
|
2014
|
|||
Expected volatility
|
|
78.29
|
%
|
|
73.38
|
%
|
|
80.94
|
%
|
Expected term
|
|
6.0 years
|
|
|
6.0 years
|
|
|
6.0 years
|
|
Risk-free interest rate
|
|
1.36
|
%
|
|
1.69
|
%
|
|
1.90
|
%
|
Expected dividend yield
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
|
Number of
Option Shares
|
|
Weighted
Average
Exercise
Price per
Share
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic
Value
|
||||
|
|
|
|
|
|
(In years)
|
|
(In thousands)
|
||||
Outstanding at December 31, 2015
|
|
2,244,177
|
|
|
$
|
8.10
|
|
|
|
|
|
|
Granted
|
|
970,950
|
|
|
$
|
15.41
|
|
|
|
|
|
|
Exercised
|
|
(152,713
|
)
|
|
$
|
3.99
|
|
|
|
|
|
|
Forfeited or expired
|
|
(108,453
|
)
|
|
$
|
14.28
|
|
|
|
|
|
|
Outstanding at December 31, 2016
|
|
2,953,961
|
|
|
$
|
10.49
|
|
|
6.82
|
|
6,376
|
|
Exercisable at December 31, 2016
|
|
1,706,310
|
|
|
$
|
8.17
|
|
|
5.62
|
|
5,857
|
|
Vested and expected to vest at December 31, 2016 (1)
|
|
2,862,624
|
|
|
$
|
10.37
|
|
|
6.75
|
|
6,348
|
|
(1)
|
Options expected to vest consist of options scheduled to vest in the future less expected forfeitures.
|
|
|
For the Year Ended December 31,
|
||||||||||
|
|
2016
|
|
2015
|
|
2014
|
||||||
Research and development
|
|
$
|
2,147
|
|
|
$
|
1,251
|
|
|
$
|
802
|
|
General and administrative
|
|
2,920
|
|
|
1,730
|
|
|
891
|
|
|||
Total stock-based compensation expense
|
|
$
|
5,067
|
|
|
$
|
2,981
|
|
|
$
|
1,693
|
|
|
For the Year Ended December 31,
|
||||||||||
|
2016
|
|
2015
|
|
2014
|
||||||
|
(in thousands, except per share amounts)
|
||||||||||
Numerator:
|
|
|
|
|
|
||||||
Net (loss) income applicable to common stockholders—basic and diluted
|
$
|
(50,720
|
)
|
|
$
|
24,174
|
|
|
$
|
(31,754
|
)
|
Denominator:
|
|
|
|
|
|
||||||
Weighted average shares outstanding - basic
|
22,233
|
|
|
21,152
|
|
|
15,842
|
|
|||
Dilutive stock options
|
—
|
|
|
1,105
|
|
|
—
|
|
|||
Dilutive warrants
|
—
|
|
|
10
|
|
|
—
|
|
|||
Weighted average shares outstanding - diluted
|
22,233
|
|
|
22,267
|
|
|
15,842
|
|
|||
Net (loss) income per share applicable to common stockholders:
|
|
|
|
|
|
||||||
Basic
|
$
|
(2.28
|
)
|
|
$
|
1.14
|
|
|
$
|
(2.00
|
)
|
Diluted
|
$
|
(2.28
|
)
|
|
$
|
1.09
|
|
|
$
|
(2.00
|
)
|
Anti-dilutive potential common stock equivalents excluded from the calculation of net (loss) income per share:
|
|
|
|
|
|
||||||
Stock options
|
620
|
|
|
429
|
|
|
1,174
|
|
|||
Warrants
|
71
|
|
|
61
|
|
|
71
|
|
|
|
Year ended December 31,
|
|||||||
|
|
2016
|
|
2015
|
|
2014
|
|||
Federal statutory income tax rate
|
|
34.0
|
%
|
|
(34.0
|
)%
|
|
34.0
|
%
|
State income taxes
|
|
4.5
|
%
|
|
(5.3
|
)%
|
|
5.3
|
%
|
Change in valuation allowance
|
|
(40.3
|
)%
|
|
32.6
|
%
|
|
(41.0
|
)%
|
Research and development and other credits
|
|
3.1
|
%
|
|
7.8
|
%
|
|
4.5
|
%
|
Permanent items
|
|
(1.0
|
)%
|
|
(0.3
|
)%
|
|
(0.7
|
)%
|
Alternative minimum tax
|
|
—
|
%
|
|
(1.7
|
)%
|
|
—
|
%
|
Other
|
|
(0.3
|
)%
|
|
(0.8
|
)%
|
|
—
|
%
|
Expiring state net operating loss carryforward
|
|
—
|
%
|
|
—
|
%
|
|
(2.1
|
)%
|
Effective income tax rate
|
|
—
|
%
|
|
(1.7
|
)%
|
|
—
|
%
|
|
|
December 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Net operating loss carryforwards
|
|
$
|
53,809
|
|
|
$
|
35,511
|
|
Deferred revenue
|
|
3,948
|
|
|
3,995
|
|
||
Research and development and other credit carryforwards
|
|
10,791
|
|
|
9,666
|
|
||
Other
|
|
3,851
|
|
|
2,769
|
|
||
|
|
72,399
|
|
|
51,941
|
|
||
Valuation allowance
|
|
(72,399
|
)
|
|
(51,941
|
)
|
||
Net deferred tax assets
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
||
|
Base rent obligations
|
||
At December 31, 2016
|
|
||
2017
|
1,573
|
|
|
2018
|
1,208
|
|
|
Total minimum lease payments
|
$
|
2,781
|
|
|
|
Three Months Ended
|
||||||||||||||
|
|
March 31,
2016
|
|
June 30,
2016
|
|
September 30,
2016
|
|
December 31,
2016
|
||||||||
|
|
(in thousands, except per share data)
(unaudited)
|
||||||||||||||
Revenue
|
|
$
|
56
|
|
|
$
|
71
|
|
|
$
|
26
|
|
|
$
|
21
|
|
Operating expenses
|
|
14,030
|
|
|
13,644
|
|
|
11,494
|
|
|
12,173
|
|
||||
Loss from operations
|
|
(13,974
|
)
|
|
(13,573
|
)
|
|
(11,468
|
)
|
|
(12,152
|
)
|
||||
Other income, net
|
|
94
|
|
|
132
|
|
|
112
|
|
|
109
|
|
||||
Net loss
|
|
$
|
(13,880
|
)
|
|
$
|
(13,441
|
)
|
|
$
|
(11,356
|
)
|
|
$
|
(12,043
|
)
|
Net loss per share - basic and diluted
|
|
$
|
(0.63
|
)
|
|
$
|
(0.60
|
)
|
|
$
|
(0.51
|
)
|
|
$
|
(0.54
|
)
|
|
|
Three Months Ended
|
||||||||||||||
|
|
March 31,
2015 |
|
June 30,
2015 |
|
September 30,
2015 |
|
December 31,
2015 |
||||||||
|
|
(in thousands, except per share data)
(unaudited)
|
||||||||||||||
Revenue
|
|
$
|
1,306
|
|
|
$
|
53,409
|
|
|
$
|
1,709
|
|
|
$
|
10,305
|
|
Operating expenses
|
|
10,177
|
|
|
11,719
|
|
|
10,403
|
|
|
9,642
|
|
||||
(Loss) Income from operations
|
|
(8,871
|
)
|
|
41,690
|
|
|
(8,694
|
)
|
|
663
|
|
||||
Other (expense) income, net
|
|
(131
|
)
|
|
(77
|
)
|
|
(21
|
)
|
|
44
|
|
||||
(Provision) Benefit for income taxes
|
|
—
|
|
|
(567
|
)
|
|
161
|
|
|
(23
|
)
|
||||
Net (loss) income
|
|
$
|
(9,002
|
)
|
|
$
|
41,046
|
|
|
$
|
(8,554
|
)
|
|
$
|
684
|
|
Net (loss) income per share—basic
|
|
$
|
(0.48
|
)
|
|
$
|
1.89
|
|
|
$
|
(0.39
|
)
|
|
$
|
0.03
|
|
Net (loss) income per share - diluted
|
|
$
|
(0.48
|
)
|
|
$
|
1.80
|
|
|
$
|
(0.39
|
)
|
|
$
|
0.03
|
|
ITEM 9.
|
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
ITEM 9A.
|
Controls and Procedures
|
•
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of a company’s assets;
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that a company’s receipts and expenditures are being made only in accordance with authorizations of the company’s management and directors; and
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
|
ITEM 9B.
|
Other Information
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position(s)
|
|
Executive Officers
|
|
|
|
|
|
Roger D. Tung, Ph. D.
|
|
57
|
|
|
President and Chief Executive Officer, Director
|
James V. Cassella, Ph.D.
|
|
62
|
|
|
Senior Vice President and Chief Development Officer
|
Ryan Daws
|
|
43
|
|
|
Chief Financial Officer
|
Ian Robert Silverman, J.D., Ph. D.
|
|
64
|
|
|
Senior Vice President and General Counsel
|
Nancy Stuart
|
|
59
|
|
|
Chief Operating Officer
|
|
|
|
|
|
|
Non-Employee Directors
|
|
|
|
|
|
Richard H. Aldrich
|
|
62
|
|
|
Director, Chairman of the Board of Directors
|
Thomas G. Auchincloss, Jr.
|
|
55
|
|
|
Director
|
Ronald W. Barrett, Ph.D.
|
|
61
|
|
|
Director
|
Meghan FitzGerald, Ph.D.
|
|
46
|
|
|
Director
|
Christine van Heek
|
|
60
|
|
|
Director
|
Peter Barton Hutt, LL.M
|
|
82
|
|
|
Director
|
Wilfred E. Jaeger, M.D.
|
|
61
|
|
|
Director
|
Wendell Wierenga, Ph.D.
|
|
69
|
|
|
Director
|
|
•
|
|
appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;
|
|
•
|
|
overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm;
|
|
•
|
|
reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;
|
|
•
|
|
monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;
|
|
•
|
|
overseeing our internal audit function, if any;
|
|
•
|
|
discussing our risk management policies;
|
|
•
|
|
establishing policies regarding hiring employees from the independent registered public accounting firm and procedures for the receipt, retention and treatment of accounting related complaints and concerns;
|
|
•
|
|
meeting independently with our internal auditing staff, independent registered public accounting firm and management;
|
|
•
|
|
reviewing and approving or ratifying any related person transactions; and
|
|
•
|
|
preparing the audit committee report required by SEC rules.
|
Name
|
|
Year
|
|
Salary
($) |
|
Bonus
($) |
|
Option awards
($)(2) |
|
Non-equity
incentive plan compensation ($) (3) |
|
All other
compensation ($) (6) |
|
Total ($)
|
||||||||
Roger D. Tung, Ph.D.
|
|
2016
|
|
499,905
|
|
|
—
|
|
|
1,937,609
|
|
|
199,962
|
|
|
9,756
|
|
|
2,647,232
|
|
||
President and Chief Executive Officer
|
|
2015
|
|
435,537
|
|
|
—
|
|
|
—
|
|
|
262,211
|
|
|
13,256
|
|
|
711,004
|
|
||
James V. Cassella, Ph.D.
|
|
2016
|
|
392,700
|
|
|
—
|
|
|
569,885
|
|
|
125,664
|
|
|
10,722
|
|
|
1,098,971
|
|
||
Senior Vice President and Chief Development Officer
|
|
2015
|
|
353,684
|
|
(4
|
)
|
40,000
|
|
(5
|
)
|
1,308,314
|
|
|
129,991
|
|
|
7,364
|
|
|
1,839,353
|
|
Nancy Stuart
|
(1)
|
2016
|
|
384,780
|
|
|
—
|
|
|
911,816
|
|
|
123,130
|
|
|
9,756
|
|
|
1,429,482
|
|
||
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Ms. Stuart was not a named executive officer for the fiscal year ended December 31, 2015, but is a named executive officer for the fiscal year ended December 31, 2016.
|
(2)
|
The amounts included in the “Option awards” column reflect the aggregate grant date fair value of option awards in the years indicated, calculated in accordance with FASB ASC Topic 718. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions. The amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the named executive officer upon exercise of the options. Assumptions used in the calculation of these amounts are included in Note 9 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.
|
(3)
|
Consists of cash bonuses earned under our 2016 and 2015 executive bonus programs with respect to the years indicated. See the “—Narrative to Summary Compensation Table” described below for a description of the 2016 executive bonus program.
|
(4)
|
Amount shown represents a sign-on bonus paid in connection with Dr. Cassella’s commencement of employment with us in February 2015.
|
(5)
|
Mr. Cassella joined Concert as our Senior Vice President and Chief Development Officer in February 2015. His annualized base salary for 2015 was $385,000.
|
(6)
|
Amounts disclosed under the column “All Other Compensation” for 2016 represent Company matching contributions to 401(k) accounts and life insurance premiums.
|
Achillion Pharmaceuticals, Inc.
|
|
Geron Corporation
|
|
Proteostasis Therapeutic, Inc.
|
|
|
|
||
Akebia Therapeutics, Inc.
|
|
GlycoMimetics, Inc.
|
|
Regulus Therapeutics, Inc.
|
|
|
|
||
Ardelyx, Inc.
|
|
Ignyta, Inc.
|
|
Sangamo Biosciences, Inc.
|
|
|
|
||
Arrowhead Research Corporation
|
|
Inovio Pharmaceuticals, Inc.
|
|
Trevena, Inc.
|
|
|
|
||
Cytokinetics, Inc.
|
|
Karyopharm Therapeutics, Inc.
|
|
Xencor, Inc.
|
|
|
|
||
Epyzime, Inc.
|
|
Mirati Therapeutics, Inc.
|
|
Ziopharm Oncology, Inc.
|
|
|
|
|
|
Genocea Biosciences, Inc.
|
|
OncoMed Pharmaceuticals, Inc.
|
|
|
|
|
Options Awards
|
|||||||||
Name
|
|
Number of securities
underlying unexercised options (#) exercisable |
|
Number of securities
underlying unexercised options (#) unexercisable |
|
Option
exercise price ($) |
|
Option
expiration date |
|||
Roger D. Tung, Ph.D.
|
|
35,097
|
|
|
—
|
|
(1)
|
4.58
|
|
|
12/19/2018
|
|
|
38,052
|
|
|
—
|
|
(2)
|
4.41
|
|
|
12/10/2019
|
|
|
29,202
|
|
|
—
|
|
(3)
|
3.79
|
|
|
12/14/2020
|
|
|
39,822
|
|
|
—
|
|
(4)
|
3.50
|
|
|
12/15/2021
|
|
|
127,063
|
|
|
76,237
|
|
(5)
|
8.40
|
|
|
6/10/2024
|
|
|
31,875
|
|
|
138,125
|
|
(6)
|
16.85
|
|
|
1/7/2026
|
James V. Cassella, Ph.D.
|
|
61,250
|
|
|
78,750
|
|
(7)
|
14.46
|
|
|
3/5/2025
|
|
|
9,375
|
|
|
40,625
|
|
(6)
|
16.85
|
|
|
1/7/2026
|
Nancy Stuart
|
|
2,098
|
|
|
—
|
|
(8)
|
1.13
|
|
|
12/11/2017
|
|
|
53,097
|
|
|
—
|
|
(1)
|
4.58
|
|
|
12/19/2018
|
|
|
34,512
|
|
|
—
|
|
(2)
|
4.41
|
|
|
12/10/2019
|
|
|
21,238
|
|
|
—
|
|
(3)
|
3.79
|
|
|
12/14/2020
|
|
|
22,122
|
|
|
—
|
|
(4)
|
3.50
|
|
|
12/15/2021
|
|
|
62,500
|
|
|
37,500
|
|
(5)
|
8.40
|
|
|
06/10/2024
|
|
|
15,000
|
|
|
65,000
|
|
(6)
|
16.85
|
|
|
01/07/2026
|
(1)
|
This stock option fully vested in accordance with its terms on December 19, 2012 and vested as to 6.25% of the underlying shares at the end of each successive quarter.
|
(2)
|
This stock option fully vested in accordance with its terms on December 10, 2013 and vested as to 6.25% of the underlying shares at the end of each successive quarter.
|
(3)
|
This stock option fully vested in accordance with its terms on December 14, 2014 and vested as to 6.25% of the underlying shares at the end of each successive quarter.
|
(4)
|
This stock option fully vested in accordance with its terms on December 15, 2015 and vested as to 6.25% of the underlying shares at the end of each successive quarter.
|
(5)
|
This option was granted under our 2014 Stock Incentive Plan and vested as to 25% of the shares underlying such option on June 10, 2015 and will vest as to an additional 6.25% of the shares at the end of each successive quarter thereafter, through and including June 10, 2018.
|
(6)
|
This option was granted under our 2014 Stock Incentive Plan and vests as to 6.25% of the shares underlying such option at the end of each successive quarter thereafter, through and including January 7, 2020.
|
(7)
|
This option was granted under our 2014 Stock Incentive Plan and vested as to 25% of the shares underlying such option on March 5, 2016 and will vest as to an additional 6.25% of the shares at the end of each successive quarter thereafter, through and including March 5, 2019.
|
(8)
|
This stock option fully vested in accordance with its terms on December 11, 2011 and vested as to 6.25% of the underlying shares at the end of each successive quarter.
|
|
•
|
|
An amount equal to 12 months (or 15 months in the case of Dr. Tung) of the named executive officer’s base salary, which will be paid as a lump sum if the change in control constitutes a change in control under Section 409A of the Internal Revenue Code.
|
|
•
|
|
An amount equal his or her current target bonus (or 1.5 times his target bonus in the case of Dr. Tung).
|
|
•
|
|
Continue Company paid medical and dental benefits to the executive to the extent that he or she was receiving them at the time of termination for until the earlier of 12 months (or 18 months in the case of Dr. Tung) following termination and the date the named executive officer’s COBRA continuation coverage expires, subject to certain legal restrictions.
|
Name
|
|
Cash
Severance ($)(1) |
|
Bonus
($)(2) |
|
COBRA
Continuation ($)(3) |
|
Value of
Accelerated Vesting of Equity Awards ($)(4) |
|
Total ($)
|
|||||
Roger D. Tung
|
|
|
|
|
|
|
|
|
|
|
|||||
Qualifying termination not in connection with a change of control
|
|
624,881
|
|
|
—
|
|
|
34,214
|
|
|
—
|
|
|
659,095
|
|
Qualifying termination in connection with a change of control
|
|
749,858
|
|
|
374,929
|
|
|
41,057
|
|
|
144,088
|
|
|
1,309,932
|
|
James V. Cassella
|
|
|
|
|
|
|
|
|
|
|
|||||
Qualifying termination not in connection with a change of control
|
|
392,700
|
|
|
—
|
|
|
27,371
|
|
|
—
|
|
|
420,071
|
|
Qualifying termination in connection with a change of control
|
|
392,700
|
|
|
157,080
|
|
|
27,371
|
|
|
0
|
|
|
577,151
|
|
Nancy Stuart
|
|
|
|
|
|
|
|
|
|
|
|||||
Qualifying termination not in connection with a change of control
|
|
384,780
|
|
|
—
|
|
|
27,371
|
|
|
—
|
|
|
412,151
|
|
Qualifying termination in connection with a change of control
|
|
384,780
|
|
|
153,912
|
|
|
27,371
|
|
|
70,875
|
|
|
636,938
|
|
(1)
|
For a termination by us without cause or by the executive for good reason, in each case not during the change of control period, this amount represents, in the case of Dr. Tung, 15 months' of base salary, and in the case of Ms. Stuart and Dr. Cassella, 12 months of base salary, each at the rate in effect immediately prior to the executive’s termination of employment.
In the event of a termination by us without cause or by the executive for good reason, in each case within 12 months of a change of control, this amount represents, in the case of Dr. Tung, 18 months' base salary, and in the case of Ms. Stuart and Dr. Cassella, 12 months of base salary, each at the rate in effect immediately prior to the executive’s termination of employment.
|
|
|
(2)
|
In the event of a termination by us without cause or by the executive for good reason, in each case within 12 months of a change of control, amounts represent in the case of Dr. Tung, 150% of his target bonus for 2016, and in the case of Ms. Stuart and Dr. Cassella, 100% of the applicable executive’s target bonus for 2016.
|
|
|
(3)
|
This amount represents the Company-paid health and dental coverage. In the case of Dr. Tung, the amounts represent 15 months payable following a termination by us without cause or by him for good reason, in each case not during the change of control period, and represents 18 months payable following a termination by us without cause or by him for good reason, in each case within 12 months of a change of control. With respect to Ms. Stuart and Dr. Cassella, amounts represent 12 months of Company-paid health and dental coverage.
|
|
|
(4)
|
In the event of a termination by us without cause, termination due to death or disability or a termination by the executive for good reason, in each case within 12 months of a change of control, all unvested stock options held by the executive at such time will immediately vest in full. The values for the accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on December 31, 2016 (i.e., the difference between the closing price of the Company’s common stock on the NASDAQ Global Market on that date and the applicable exercise price, multiplied by the number of shares for which vesting would have been accelerated).
|
|
|
|
|
|
||
|
|
Annual Member Fee ($)
|
|
Chairman Annual Fee ($)
|
||
Board of Directors
|
|
35,000
|
|
|
65,000
|
|
Audit Committee
|
|
7,500
|
|
|
15,000
|
|
Compensation Committee
|
|
5,000
|
|
|
10,000
|
|
Nominating and Corporate Governance Committee
|
|
3,000
|
|
|
7,000
|
|
|
|
|
|
|
|
|
|||
Name
|
|
Fees earned or
paid in cash ($) |
|
Option awards ($)(1)
|
|
Total ($)
|
|||
Richard H. Aldrich
|
|
74,802
|
|
|
87,201
|
|
|
162,003
|
|
Thomas G. Auchincloss, Jr.
|
|
47,802
|
|
|
87,201
|
|
|
135,003
|
|
Ronald W. Barrett, Ph.D.
|
|
42,802
|
|
|
87,201
|
|
|
130,003
|
|
Meghan FitzGerald, Ph.D.
|
|
29,876
|
|
|
231,335
|
|
|
261,211
|
|
Christine van Heek
|
|
30,103
|
|
|
218,003
|
|
|
248,106
|
|
Peter Barton Hutt
|
|
35,802
|
|
|
87,201
|
|
|
123,003
|
|
Wilfred E. Jaeger, M.D.
|
|
45,302
|
|
|
87,201
|
|
|
132,503
|
|
Helmut M. Sch
ü
hsler, Ph.D. (2)
|
|
7,762
|
|
|
0
|
|
|
7,762
|
|
Wendell Wierenga, Ph.D.
|
|
35,802
|
|
|
87,201
|
|
|
123,003
|
|
(1)
|
The amounts included in the “Option awards” column reflect the aggregate grant date fair value of options granted during 2016 calculated in accordance with FASB ASC Topic 718. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions. The amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the director upon exercise of the options. Assumptions used in the calculation of these amounts are included in Note 9 to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. As of December 31, 2016:
|
|
•
|
|
Mr. Aldrich held stock options to purchase 41,236 shares of common stock in the aggregate, of which 36,236 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2017;
|
|
•
|
|
Mr. Auchincloss held stock options to purchase 45,000 shares of common stock in the aggregate, of which 31,667 shares were vested, with the remaining shares scheduled to vest through and including December 11, 2017;
|
|
•
|
|
Dr. Barrett held stock options to purchase 34,156 shares of common stock in the aggregate, of which 29,156 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2017;
|
|
•
|
|
Dr. FitzGerald held stock options to purchase 25,000 shares of common stock in the aggregate, of which 6,250 shares were vested, with the remaining shares scheduled to vest through and including March 22, 2019;
|
|
•
|
|
Ms. van Heek held stock options to purchase 25,000 shares of common stock in the aggregate, of which 4,167 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2019;
|
|
•
|
|
Mr. Hutt held stock options to purchase 34,156 shares of common stock in the aggregate, of which 29,156 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2017;
|
|
•
|
|
Dr. Jaeger held a stock option to purchase 20,000 shares of common stock, of which 15,000 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2017;
|
|
•
|
|
Dr. Wierenga held a stock option to purchase 48,538 shares of common stock, of which 41,455 shares were vested, with the remaining shares scheduled to vest through and including June 9, 2017.
|
(2)
|
Dr. Schühsler provided notice of his resignation from our Board of Directors effective as of the close of business on April 8, 2016. Dr. Schühsler held vested stock options to purchase 7,500 shares of common stock as of his resignation date, which were exercisable through July 7, 2016.
|
|
•
|
|
each of our directors and our director nominees;
|
|
•
|
|
each of our named executive officers;
|
|
•
|
|
all of our directors, our director nominees and executive officers as a group; and
|
|
•
|
|
each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.
|
Name of beneficial owner
|
|
Number of
shares beneficially owned |
|
Percentage
of shares beneficially owned |
||
5% Stockholders
|
|
|
|
|
||
Entities affiliated with BVF, Inc.
(1)
|
|
2,616,249
|
|
|
11.7
|
%
|
Entities affiliated with TVM Capital
(2)
|
|
1,483,672
|
|
|
6.6
|
%
|
Entities affiliated with GlaxoSmithKline
(3)
|
|
1,356,533
|
|
|
6.1
|
%
|
Entities affiliated with BlackRock Inc.
(4)
|
|
1,127,145
|
|
|
5.0
|
%
|
|
|
|
||||
Executive Officers and Directors
|
|
|
|
|
||
Roger D. Tung, Ph.D.
(5)
|
|
1,010,943
|
|
|
4.5
|
%
|
James V. Cassella, Ph.D.
(6)
|
|
82,500
|
|
|
*
|
|
Nancy Stuart
(7)
|
|
260,768
|
|
|
1.2
|
%
|
Richard H. Aldrich
(8)
|
|
470,062
|
|
|
2.1
|
%
|
Thomas G. Auchincloss
(9)
|
|
38,250
|
|
|
*
|
|
Ronald W. Barrett, Ph.D.
(10)
|
|
31,656
|
|
|
*
|
|
Meghan FitzGerald, Ph.D.
(11)
|
|
8,333
|
|
|
*
|
|
Christine van Heek
(12)
|
|
6,250
|
|
|
*
|
|
Peter Barton Hutt, LL.M
(13)
|
|
36,080
|
|
|
*
|
|
Wilfred E. Jaeger, M.D.
(14)
|
|
17,500
|
|
|
*
|
|
Wendell Wierenga, Ph.D.
(15)
|
|
58,427
|
|
|
*
|
|
All current executive officers and directors as a group (13 persons)
(16)
|
|
2,020,769
|
|
|
10.1
|
%
|
*
|
Represents beneficial ownership of less than 1% of our outstanding stock.
|
(1)
|
Based on information set forth in a Schedule 13G filed with the Securities and Exchange Commission on February 14, 2017 by the following entities and individual. Consists of (i) 1,193,342 shares of common stock beneficially owned by Biotechnology Value Fund, L.P. (“BVF”), (ii) 758,494 shares of common stock beneficially owned by Biotechnology Value Fund II, L.P (“BVF2”) and (iii) 238,511 shares of common stock beneficially owned by Biotechnology Value Trading Fund OS LP (“Trading Fund OS”). BVF Partners OS Ltd. (“Partners OS”) as the general partner of Trading Fund OS may be deemed to beneficially own the 238,511 shares of Common Stock beneficially owned by Trading Fund OS. BVF Partners L.P. (“Partners”), as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,232,014 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners management accounts (the “Partners Management Accounts”), including 425,902 shares of Common Stock held in the Partners Management Accounts. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,616,249 shares of Common Stock beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,616,249 shares of Common Stock beneficially owned by BVF Inc. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Management Accounts. The address for Trading Fund OS and Partners OS is PO Box 309 Ugland House, Grand Cayman, KY1-1104 Cayman Islands and the address for each of the other entities and for Mr. Lampert is 1 Sansome Street, 30
th
Floor, San Francisco, California 94104.
|
(2)
|
Based on information set forth in a Schedule 13G filed with the Securities and Exchange Commission on February 16, 2016. Consists of 1,104,969 shares of common stock held by TVM Life Science Ventures VI GMBH & Co. KG and 378,703 shares of common stock held by TVM Life Science Ventures VI LP. Alexandra Goll, Helmut Schühsler, Hubert Birner, Stefan Fischer and Axel Polack are members of the investment committee of TVM Life Science Ventures VI Management Limited Partnership, a special limited partner of TVM Life Science Ventures VI GMBH & Co. KG and TVM Life Science Ventures VI LP with voting and dispositive power over the shares held by those entities. TVM Life Science Venture VI Management Limited Partnership and these individuals each disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address for each of the individuals and entities listed above is c/o TVM Capital GmbH, Maximilianstrasse 35, Entrance C, 80539 Munich, Germany.
|
(3)
|
Based on information set forth in a Schedule 13G filed with the Securities and Exchange Commission on February 13, 2015 by GlaxoSmithKline plc. Consists of 1,179,941 shares of common stock held by Glaxo Group Limited and 176,592 shares of common stock held by S.R. One, Limited, each of which is a wholly owned subsidiary of GlaxoSmithKline plc. The address of these entities is 980 Great West Road, Brentford, Middlesex, United Kingdom TW8 9GS.
|
(4)
|
Based on information set forth in a Schedule 13G filed with the Securities and Exchange Commission on January 23, 2017 by BlackRock, Inc. Consists of 1,127,145 shares of common stock beneficially owned by BlackRock, Inc. The address for BlackRock, Inc. is 55 East 52nd Street, New York, NY, 10055.
|
(5)
|
In addition to shares of common stock held directly, includes 121,873 shares of common stock held by the Roger D. Tung 2011 GRAT, for which Dr. Tung is the sole trustee, 12,389 shares of common stock held by the RD Tung Irrevocable Trust, for which Dr. Tung’s wife is a co-trustee, and 13,274 shares of common stock held by the Tung Family Investment Trust, for which Dr. Tung is a co-trustee. Includes 324,442 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(6)
|
Consists of 82,500 shares of common stock issuable upon exercise of options exercisable within 60 days after January 31, 2017.
|
(7)
|
In addition to shares of common stock held directly, includes 221,817 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(8)
|
In addition to shares of common stock held directly, includes 61,946 shares of common stock held by Little Bear Associates, Inc., formerly known as RA Capital Associates, Inc., of which Mr. Aldrich is the sole stockholder, and 82,405 shares of common stock held by the Little Eagles, LLC, of which the owners of Little Eagles, LLC are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of the Mr. Aldrich's minor children. The trustees of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's spouse, Nichole A. Aldrich, and Mr. Aldrich's brother, Caleb F. Aldrich. The beneficiaries of Richard H. Aldrich Irrevocable Trust of 2011 are Mr. Aldrich's minor children. Mr. Aldrich disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Includes 38,736 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(9)
|
In addition to shares of common stock held directly, includes 36,250 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(10)
|
Consists of 31,656 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(11)
|
Consists of 8,333 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(12)
|
Consists of 6,250 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(13)
|
In addition to shares held directly, includes 31,656 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(14)
|
Includes 17,500 shares of common stock issuable upon the exercise of options exercisable within 60 days after March 31, 2016.
|
(15)
|
In addition to shares held directly, includes 46,038 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
(16)
|
Includes 1,167,120 shares of common stock issuable upon the exercise of options exercisable within 60 days after January 31, 2017.
|
|
•
|
|
the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity;
|
|
•
|
|
the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction with us and do not receive any special benefits as a result of the transaction; and
|
|
•
|
|
the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenue of the company receiving payment under the transaction.
|
|
•
|
|
the related person’s interest in the related person transaction;
|
|
•
|
|
the approximate dollar value of the amount involved in the related person transaction;
|
|
•
|
|
the approximate dollar value of the amount of the related person’s interest in the transaction without regard to the amount of any profit or loss;
|
|
•
|
|
whether the transaction was undertaken in the ordinary course of business of our company;
|
|
•
|
|
whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the terms that could have been reached with an unrelated third party;
|
|
•
|
|
the purpose of, and the potential benefits to us of, the transaction; and
|
|
•
|
|
any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.
|
Fee Category
|
|
2016
|
|
2015
|
||||
Audit Fees
(1)
|
|
$
|
423,535
|
|
|
$
|
425,750
|
|
Audit-Related Fees
|
|
—
|
|
|
—
|
|
||
Tax Fees
(2)
|
|
37,960
|
|
|
77,950
|
|
||
All Other Fees
(3)
|
|
2,000
|
|
|
2,000
|
|
||
Total Fees
|
|
$
|
463,495
|
|
|
$
|
505,700
|
|
(1)
|
Audit fees for 2016 and 2015 consist of fees for the audit of our consolidated financial statements and the review of our interim financial statements. Audit fees for 2015 also include fees associated with the March 2015 public offering.
|
(2)
|
Tax fees consists of fees incurred for tax compliance and tax return preparation.
Tax fees for 2016 and 2015 also include fees incurred in connection with preparation of an ownership analysis pursuant to Section 382 of the Internal Revenue Code to quantify any limitations on the availability of net operating loss carryforwards to offset taxable income.
|
(3)
|
All Other Fees represents payment for access to the Ernst & Young LLP online accounting research database.
|
ITEM 15.
|
Exhibits and Financial Statement Schedules
|
(1)
|
Financial Statements
|
(2)
|
Financial Statement Schedules
|
(3)
|
Exhibits
|
|
|
|
|
|
CONCERT PHARMACEUTICALS, INC.
|
|
|
|
By:
|
|
/s/ Roger D. Tung
|
|
|
Roger D. Tung, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
||
/s/ Roger D. Tung
|
|
Director, President and Chief Executive Officer (Principal Executive Officer)
|
|
March 6, 2017
|
Roger D. Tung, Ph.D.
|
|
|
||
|
|
|
||
/s/ Ryan Daws
|
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
|
March 6, 2017
|
Ryan Daws
|
|
|
||
|
|
|
||
/s/ Richard H. Aldrich
|
|
Chairman
|
|
March 6, 2017
|
Richard H. Aldrich
|
|
|
||
|
|
|
||
/s/ Thomas G. Auchincloss
|
|
Director
|
|
March 6, 2017
|
Thomas G. Auchincloss
|
|
|
||
|
|
|
||
/s/ Ronald W. Barrett
|
|
Director
|
|
March 6, 2017
|
Ronald W. Barrett, Ph.D.
|
|
|
||
|
|
|
|
|
/s/ Meghan FitzGerald
|
|
Director
|
|
March 6, 2017
|
Meghan FitzGerald, Ph.D.
|
|
|
||
|
|
|
|
|
/s/ Christine van Heek
|
|
Director
|
|
March 6, 2017
|
Christine van Heek
|
|
|
||
|
|
|
||
/s/ Peter Barton Hutt
|
|
Director
|
|
March 6, 2017
|
Peter Barton Hutt
|
|
|
||
|
|
|
||
/s/ Wilfred E. Jaeger
|
|
Director
|
|
March 6, 2017
|
Wilfred E. Jaeger, M.D.
|
|
|
||
|
|
|
||
/s/ Wendell Wierenga
|
|
Director
|
|
March 6, 2017
|
Wendell Wierenga, Ph.D.
|
|
|
Exhibit
number
|
|
Description
|
|
|
|
10.11 #*
|
|
Amended and Restated Employment Agreement, dated March 1, 2017, by and between the Registrant and Ian Robert Silverman
|
|
|
|
10.12 *
|
|
Asset Purchase Agreement, dated March 3, 2017, by and between the Registrant and Vertex Pharmaceuticals (Europe) Ltd., as Buyer, and Vertex Pharmaceuticals Inc., as Guarantor
|
|
|
|
10.13 #
|
|
Form of Director and Officer Indemnification Agreement by and between the Registrant and each of Roger D. Tung, Nancy Stuart, D. Ryan Daws, Ian Robert Silverman, Pauline McGowan, Richard H. Aldrich, Thomas Auchincloss, Jr. Ronald W. Barrett, John G. Freund, Peter Barton Hutt, Wilfred E. Jaeger, Helmut M. Schühsler and Wendell Wierenga (incorporated by reference to Exhibit 10.13 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on January 13, 2014)
|
|
|
|
10.14
|
|
Lease Agreement, dated as of February 12, 2008, by and between the Registrant and One Ledgemont LLC (incorporated by reference to Exhibit 10.15 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on January 13, 2014)
|
|
|
|
10.15
|
|
Amendment of Lease, dated as of August 6, 2014, by and between the Registrant and 128 Spring Street Lexington, LLC (incorporated by reference to Exhibit 10.4 to the Registrant’s quarterly report on Form 10-Q (File No. 001-36310), filed with the SEC on August 12, 2014)
|
|
|
|
10.16 †
|
|
Development and License Agreement, dated as of February 24, 2012, between the Registrant and Avanir Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.16 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on February 3, 2014)
|
|
|
|
10.17 †
|
|
Development and License Agreement, dated as of February 26, 2013, between the Registrant and Jazz Pharmaceuticals Ireland Limited (incorporated by reference to Exhibit 10.17 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on February 3, 2014)
|
|
|
|
10.18 †
|
|
Amendment No. 1, dated February 26, 2015, to Development and License Agreement dated February 26, 2013 by and between the Registrant and Jazz Pharmaceuticals Ireland Limited (incorporated by reference to Exhibit 10.1 to the Registrant’s quarterly report on Form 10-Q (File No. 001-36310), filed with the SEC on May 11, 2015)
|
|
|
|
10.19 †
|
|
Master Development and License Agreement, dated as of April 4, 2013, among the Registrant, Celgene International Sàrl and Celgene Corporation (incorporated by reference to Exhibit 10.18 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on February 3, 2014)
|
|
|
|
10.20 †
|
|
Patent Assignment Agreement, dated September 8, 2011, by and between the Registrant and Auspex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s quarterly report on Form 10-Q (File No. 001-36310), filed with the SEC on May 11, 2015)
|
|
|
|
10.21 #
|
|
Summary of Executive Bonus Program (incorporated by reference to Exhibit 10.19 to the Registrant’s registration statement on Form S-1 (File No. 333-193335), filed with the SEC on January 13, 2014)
|
|
|
|
10.22 #*
|
|
Summary of Director Compensation Program
|
|
|
|
21.1*
|
|
Subsidiaries of the Registrant
|
|
|
|
23.1*
|
|
Consent of Ernst & Young LLP
|
|
|
|
31.1*
|
|
Chief Executive Officer—Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
31.2*
|
|
Chief Financial Officer—Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
32.1**
|
|
Chief Executive Officer—Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.2**
|
|
Chief Financial Officer—Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
*
|
Filed herewith.
|
**
|
Furnished herewith.
|
†
|
Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
|
#
|
Management contracts or compensatory plans or arrangements required to be filed as an exhibit hereto pursuant to Item 15(a) of Form 10-K.
|
|
|
|
|
Very truly yours,
|
|
|
|
||
|
|
|
|
|
|
|
|
|
/s/ Roger D. Tung
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
||
Agreed and Accepted:
|
|
|
|
|
|
|
|
||
Signature:
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Date:
|
|
|
|
|
Very truly yours,
|
|
|
|
|
|
Accepted and Agreed
|
|
By:
|
/s/ Roger D. Tung
|
|
|
|
|
|
|
By:
|
/s/ Ian Robert Silverman
|
|
|
1 March 2017
|
|
|
|
|
Date
|
|
Member
Annual Fee |
|
Chairman
Annual Fee |
|
||
Board of Directors
|
35,000
|
|
|
65,000
|
|
|
Audit Committee
|
7,500
|
|
|
15,000
|
|
|
Compensation Committee
|
5,000
|
|
|
10,000
|
|
|
Nominating and Corporate Governance Committee
|
3,000
|
|
|
7,000
|
|
|
|
|
|
Name
|
|
Jurisdiction of Organization
|
Concert Pharmaceuticals Securities Corporation
|
|
Massachusetts
|
Concert Pharma U.K. Ltd
|
|
United Kingdom
|
1.
|
I have reviewed this Annual Report on Form 10-K of Concert Pharmaceuticals, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
Date: March 6, 2017
|
|
/s/ Roger D. Tung
|
Roger D. Tung
|
President and Chief Executive Officer
|
1.
|
I have reviewed this Annual Report on Form 10-K of Concert Pharmaceuticals, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
Date: March 6, 2017
|
|
/s/ Ryan Daws
|
Ryan Daws
|
Chief Financial Officer
|
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
Dated: March 6, 2017
|
|
|
|
/s/ Roger D. Tung
|
|
|
|
|
Roger D. Tung
|
|
|
|
|
President and Chief Executive Officer
|
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
Dated: March 6, 2017
|
|
|
|
/s/ Ryan Daws
|
|
|
|
|
Ryan Daws
|
|
|
|
|
Chief Financial Officer
|